UBS initiated coverage of Merus (MRUS) with a Buy rating and $72 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. Merus has a “best-in-class” bispecific antibody to transform the standard of care in head and neck cancer, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Bicara Therapeutics initiated with an Overweight at Morgan Stanley
- Bicara Therapeutics initiated with an Overweight at Morgan StanleyMerus
- Merus price target raised to $111 from $93 at Guggenheim
- Merus announces first patient dosed in LiGeR-HN1 Phase 3 trial
- Merus announces abstract accepted for presentation at ESMO Asia Congress 2024